Research: Asahi’s Direct R&D on Botanicals and Nootropics

Asahi R&D on Botanicals, Nootropics, and Functional Ingredients

As shifting consumer attitudes toward alcohol continue to drive the growth of the No/Low (NoLo) category, asahi-group-holdings has pivoted its research and development (R&D) strategy to focus heavily on health, wellness, and functional ingredients [3, 12]. Recognizing that traditional premiumization of alcohol is insufficient to capture future growth, Asahi is investing in proprietary biotics, yeast derivatives, and partnerships for adaptogens and nootropics to build a robust multi-beverage-strategy [11, 12].

Strategic R&D Framework

Asahi’s functional ingredient research is primarily driven by Asahi Quality & Innovations, Ltd. (AQI), an independent R&D subsidiary established to focus on fundamental technologies, applied research, and new business incubation [11]. AQI utilizes a “backcasting” approach—analyzing projected megatrends for the year 2050 to dictate current research themes [11, 12].

This framework aims to deliver “glocal” (global and local) value by spanning three core domains:

1. Alcohol Innovation: Creating new value to cater to changing consumption behaviors.
2. Health & Wellness: Enhancing physical and mental health through functional ingredients.
3. Sustainability: Mitigating environmental risks [3].

By exploring materials that offer psychological and physiological benefits, Asahi aims to seamlessly integrate these discoveries into adult-soft-drinks, non-alcoholic beverages, and supplements, thereby supporting its broader smart-drinking-asahi moderation initiative [5, 8].

Proprietary Biotics and Mental Wellness

While the functional beverage industry frequently relies on plant-based adaptogens, Asahi’s proprietary R&D edge lies in microbiota, lactic acid bacteria, and yeast [1, 10]. Leveraging decades of research originating from its calpis brand, Asahi has successfully linked gut health to mental wellness and mood regulation [2].

• lactobacillus-gasseri-cp2305: A flagship proprietary postbiotic discovered by Asahi. Clinical studies have demonstrated its potential to alleviate stress, improve sleep quality, and manage menopausal symptoms [2, 12].
• Bacteroides uniformis: A microbial material researched by Asahi for its potential to enhance physical endurance and exercise performance [3].
• Yeast Mannan: Developed from Asahi’s brewing expertise, this yeast-based ingredient is undergoing clinical research for its ability to improve sleep quality and bowel habits [12].

These ingredients provide a scientific foundation for functional-premiumization in Asahi’s beverage and supplement lines, such as the rapidly growing dear-natura brand [12].

Botanical and Nootropic Industry Integration

The broader functional beverage market is increasingly turning to nootropics, adaptogens (such as ashwagandha), and botanicals to replace the relaxing “buzz” of alcohol [4, 7]. To compete with specialized functional brands like kin-euphorics, Asahi employs a collaborative approach to botanical integration [9].

Representatives from asahi-europe-and-international actively participate in global innovation summits alongside leading adaptogenic formulators to monitor the evolution of mood-enhancing beverages [9]. Because botanicals can introduce formulation challenges—such as astringency, poor mouthfeel, and functional degradation when exposed to light or heat—beverage makers rely heavily on strategic partners to achieve taste parity and shelf stability [4].

B2B Global Expansion and Partnerships

To monetize its R&D beyond its own consumer products, asahi-group-foods has established a global B2B raw materials business, exporting yeast products (like Yeastock) and functional lactic acid bacteria [10].

A critical component of this strategy is Asahi’s exclusive distribution agreement with ADM (adm-wild-valencia) [2, 12]. Beginning in 2024, ADM secured the rights to distribute Asahi’s CP2305 to food and beverage manufacturers across North America, Europe, and Asia [2]. This partnership acts as a two-way conduit: Asahi scales its proprietary biotics globally through ADM’s vast network, while simultaneously gaining access to ADM’s extensive portfolio of natural botanical extracts and taste modulators [2, 4]. This synergy enables effective ingredient-stacking—combining Asahi’s evidence-backed biotics with trending botanical adaptogens to create comprehensive, mood-boosting adult-soft-drinks [4].

Contradictions and Research Gaps

• Proprietary Botanicals vs. Biotics: While search results frequently associate Asahi with the functional wellness trend (which includes adaptogens and nootropics), Asahi’s direct, proprietary R&D focuses overwhelmingly on lactic acid bacteria and yeast derivatives rather than the direct cultivation or patenting of botanical nootropics [3, 10]. Their involvement with botanicals appears primarily mediated through flavoring and ingredient partnerships (e.g., ADM).
• The clinical-substantiation-gap: While Asahi possesses robust clinical data for its CP2305 postbiotic [2], the broader industry integration of adaptogenic botanicals into RTD beverages still faces scrutiny regarding whether beverage-sized doses survive processing to deliver measurable psychoactive or physiological effects [4].

Suggested Additional Sources

To further expand this topic, research should target:

• Efficacy studies regarding the survivability of CP2305 when subjected to standard beverage pasteurization.
• Clinical trials funded by Asahi regarding the synergistic effects of combining lactic acid bacteria with botanical adaptogens (e.g., ashwagandha or L-theanine).
• Financial disclosures from asahi-group-holdings detailing exact R&D budget allocations for the AQI subsidiary compared to traditional brewing operations.

References

1. Microbiota Research | Fundamental Technologies | R&D | ASAHI GROUP HOLDINGS — asahigroup-holdings.com
2. ADM and Asahi Group Sign Exclusive Distribution Agreement for Innovative Postbiotic Designed to Support Stress, Mood and Sleep | ADM — adm.com
3. R&D | ASAHI GROUP HOLDINGS — asahigroup-holdings.com
4. Adaptogens, botanical extracts help beverage-makers meet consumers’ need states | Beverage Industry — bevindustry.com
5. Product Development | R&D | ASAHI GROUP HOLDINGS — asahigroup-holdings.com
6. Protein — foodnavigator-asia.com
7. A review on packed non-alcoholic beverages - ScienceDirect.com — sciencedirect.com
8. [PDF] RESEARCH AND DEVELOPMENT — asahigroup-holdings.com
9. Just Drinks Presents: 14th Innovation in Non-Alcoholic Beverages 2025 - Arena International — arena-international.com
10. Our Business｜Asahi Group Foods — asahi-gf.co.jp
11. Asahi Quality & Innovations, Ltd. (AQI) | R&D | ASAHI GROUP HOLDINGS — asahigroup-holdings.com
12. Beer maker Asahi sets sights on health and wellness … — nutraingredients.com